Additional testing revealed that anti-CD45.2 BB700, unlike anti-CD45.2 AF647, continuing to label circulating immune system cells six hours following IP antibody injection robustly. that IP anti-CD45.2 antibody shot allowed for the recognition of ~seven instances as much tumor-specific CD8+ T cells that had recently migrated from bloodstream into tumors. Our outcomes demonstrate how different shot […]